Beyond The Checkpoint — Next-Gen Strategies In Immuno-Oncology

Join Sarah Anderson, Therapeutic Strategy Director of Oncology at Novotech, along with Izabela Chmielewska of Citeline, for an in-depth discussion on how next-generation immuno-oncology approaches are redefining the future of cancer research.

In this session, they delve into breakthrough therapeutic modalities, innovative and data-driven clinical trial designs, and the shifting regulatory landscape that is shaping development strategies worldwide. Gain a clearer view of the scientific, operational, and regulatory forces propelling the next wave of oncology innovation — and what they mean for sponsors advancing cutting-edge cancer therapies.